2014's top five US IPO companies still hot this year
This article was originally published in Scrip
Executive Summary
Three of the top five drug development firms that completed initial public offerings in the US in 2014 are focused on chimeric antigen receptor T-cell (CAR-T) therapies, but all five of the highest-grossing IPO players last year have one thing in common: later-stage assets for the treatment of high-value indications, like cancer, multiple sclerosis (MS) and anemia.